ArticleVeterinary ophthalmology2026
Sustained Tear Film Exposure After Parenteral Cefovecin Administration in Dogs: Pharmacokinetics and Relevance to Canine Bacterial Keratitis.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo characterize the tear film pharmacokinetics of parenterally administered cefovecin (Convenia) and compare tear concentrations with the minimum inhibitory concentrations (MICs) of common ocular pathogens. ANIMALS STUDIED: Six healthy research-bred Beagles. PROCEDURES: Dogs received a single subcutaneous injection of cefovecin (8 mg/kg) after inducing blood-tear barrier disruption through histamine-mediated conjunctivitis. Tear fluid was collected using Schirmer strips at multiple time points up to 336 h and analyzed via liquid chromatography-mass spectrometry. Tear concentrations from both eyes were averaged for analysis. MIC values were determined for Staphylococcus pseudintermedius, Streptococcus canis, and Pseudomonas aeruginosa (n = 10 isolates per species).
resultsIn a pilot experiment (n = 1 dog), tear cefovecin concentrations were 1.5 to 430-fold higher in the conjunctivitis eye than in the control eye at all but one time point. Across all dogs, tear concentrations ranged from 68 to 73 035 ng/mL and remained detectable throughout the 336-h study. Mean ± SD pharmacokinetic parameters were: C
conclusionsParenteral cefovecin achieved sustained tear concentrations sufficient to inhibit some susceptible Streptococcus and Staphylococcus isolates in vitro for clinically relevant time windows. While these findings support further investigation of cefovecin as an adjunctive therapy in selected cases, they do not justify empiric systemic antimicrobial use. Larger pharmacokinetic and clinical studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.